<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110757">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656265</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 197-008</org_study_id>
    <nct_id>NCT01656265</nct_id>
  </id_info>
  <brief_title>Study of ARQ 197 in Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Company, Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Company, Limited</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in
      hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the
      recommended dose of ARQ 197 in advanced HCC patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability</measure>
    <time_frame>DLT observation period will be the first 28 days after the start of ARQ 197 treatment.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Event collection and assessment will be done for all treated subjects to assess the safety, tolerability.  The grading for the severity of the adverse events will be determined according to CTCAE ver 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profiles of Pharmacokinetics</measure>
    <time_frame>Plasma sample correction at pre-dose 1, 2, 4, 6, 10, 12 and 24 hours on day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on day 15; and at pre-dose on day 29.</time_frame>
    <safety_issue>No</safety_issue>
    <description>maximum concentration (Cmax), area under the curve (AUC), half-life (t1/2), apparent clearance (Cl/F), and apparent volume of distribution in the terminal elimination phase (Vz/F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effects according to RECIST 1.1.</measure>
    <time_frame>Every 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ARQ 197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 197</intervention_name>
    <description>Daily repeating dose of oral ARQ 197, twice a day just after meals.  Dose of ARQ 197 will be escalated according to 3+3 rule.</description>
    <arm_group_label>ARQ 197</arm_group_label>
    <other_name>Tivantinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic
             sorafenib therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Child-Pugh classification A at the time of registration

          -  Adequate bone marrow, liver, and renal functions within 14 days prior to registration

        Exclusion Criteria:

          -  Prior therapy with a c-Met inhibitor (including ARQ 197)

          -  Any systemic anti-tumor treatment or investigational agent within 2 weeks prior to
             registration. If the treatment/agent was antibody, within 4 weeks

          -  Local treatment for malignancy within 4 weeks prior to registration

          -  Major surgical procedure within 4 weeks prior to registration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kashiwa-city</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>July 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
